EHA 2022 — Game Changers for Australian haematologists

Join the limbic and expert panels in Sydney and Brisbane as they present the best from the EHA2022 Congress and discuss the impacts for patient care. Attend a live event and enjoy dinner with your colleagues, or watch online from...

Join the limbic and expert panels in Sydney and Brisbane as they present the best from the EHA2022 Congress and...
Blood cancers

EHA 2022: Low intensity regimen preferred as first line therapy in Burkitt lymphoma

An investigation into the optimal first line chemotherapy treatment for high-risk Burkitt lymphoma (BL) has shown that a low intensity DA-EPOCH-R regimen appears to be preferable given its lower risk of toxicity. Results from the first prospective randomised trial comparing two...

An investigation into the optimal first line chemotherapy treatment for high-risk Burkitt lymphoma (BL) has shown that a low intensity...

ON DEMAND: EHA Game Changers – Melbourne

Watch again as an expert panel present their selection of transformational clinical data from the EHA2022 Congress and discuss the impacts for practice. Hosted by Professor Hang Quach Director of Clinical Haematology Service...

Watch again as an expert panel present their selection of transformational clinical data from the EHA2022 Congress and...